Etiqueta: heart disease

The adult stem cell company Osiris Therapeutics accomplishes an historic milestone by completing patient enrollment in the first phase III clinical trial ever to be conducted with adult stem cells in the treatment of Graft versus Host Disease.

Although legitimate adult stem cell therapies are already available, there is also no shortage of bogus stem cell therapies which erroneously claim to offer benefits.

Researchers at Children’s Hospital in Pittsburgh announce that human adult stem cells derived from skeletal muscle have successfully repaired damaged heart tissue more effectively than previously studied therapies.

Doctors announce the successful treatment of pulmonary hypertension with autologous adult stem cells in a clinical trial.

The father of embryonic stem cell science, Dr. James Thomson, merges 3 stem cell companies together into one new commercial endeavor.

Cardiologists in Germany have pioneered a new procedure for the use of adult stem cells derived from umbilical cord blood to grow new heart valves for the repair of congenital heart defects in newborns.

As yet another indication of the economic maturation of an industry, the pharmaceutical giant Pfizer is now developing anti-aging stem cell products.

The biotech company Mesoblast Ltd., specializing in regenerative medicine, is awarded a prestigious award for its adult stem cell technology.

Lured by the promise of financial profit, the pharmaceutical giant Pfizer joins the stem cell community.

In an effort to develop adult stem cell therapies that are specifically targeted to counteracting the biological dangers of nuclear warfare, the U.S. Deparment of Defense has awarded a $224.7 million contract to an Osiris-Genzyme partnership.